C
Cullinan Oncology D
D
CGEM
17.280
USD
-0.39
(-2.21%)
مغلق
حجم التداول
21,060
الربح لكل سهم
-3
العائد الربحي
-
P/E
-5
حجم السوق
1,061,995,035
العنوان: Cullinan Therapeutics
القطاع: Healthcare
الصناعة: Biotechnology
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.